285 related articles for article (PubMed ID: 30367225)
21. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
23. Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer.
Gradecki SE; Grange JS; Stelow EB
Am J Surg Pathol; 2018 Aug; 42(8):1090-1094. PubMed ID: 29794870
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice.
Rouanne M; Radulescu C; Adam J; Allory Y
World J Urol; 2021 May; 39(5):1345-1355. PubMed ID: 33141317
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.
Silva MA; Ryall KA; Wilm C; Caldara J; Grote HJ; Patterson-Kane JC
PLoS One; 2018; 13(6):e0196464. PubMed ID: 29874226
[TBL] [Abstract][Full Text] [Related]
27. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.
Lantuejoul S; Sound-Tsao M; Cooper WA; Girard N; Hirsch FR; Roden AC; Lopez-Rios F; Jain D; Chou TY; Motoi N; Kerr KM; Yatabe Y; Brambilla E; Longshore J; Papotti M; Sholl LM; Thunnissen E; Rekhtman N; Borczuk A; Bubendorf L; Minami Y; Beasley MB; Botling J; Chen G; Chung JH; Dacic S; Hwang D; Lin D; Moreira A; Nicholson AG; Noguchi M; Pelosi G; Poleri C; Travis W; Yoshida A; Daigneault JB; Wistuba II; Mino-Kenudson M
J Thorac Oncol; 2020 Apr; 15(4):499-519. PubMed ID: 31870882
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
30. Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods.
Schats KA; Van Vré EA; Boeckx C; De Bie M; Schrijvers DM; Neyns B; De Meester I; Kockx MM
Arch Pathol Lab Med; 2018 Aug; 142(8):982-991. PubMed ID: 29607663
[TBL] [Abstract][Full Text] [Related]
31. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.
Scheel AH; Baenfer G; Baretton G; Dietel M; Diezko R; Henkel T; Heukamp LC; Jasani B; Jöhrens K; Kirchner T; Lasitschka F; Petersen I; Reu S; Schildhaus HU; Schirmacher P; Schwamborn K; Sommer U; Stoss O; Tiemann M; Warth A; Weichert W; Wolf J; Büttner R; Rüschoff J
Histopathology; 2018 Feb; 72(3):449-459. PubMed ID: 28851100
[TBL] [Abstract][Full Text] [Related]
32. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?
Hofman P
Expert Rev Mol Diagn; 2017 Dec; 17(12):1097-1108. PubMed ID: 29069958
[TBL] [Abstract][Full Text] [Related]
34. Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.
Melosky B; Chu Q; Juergens RA; Leighl N; Ionescu D; Tsao MS; McLeod D; Hirsh V
Cancer Treat Rev; 2018 Apr; 65():65-77. PubMed ID: 29567557
[TBL] [Abstract][Full Text] [Related]
35. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
[TBL] [Abstract][Full Text] [Related]
36. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
39. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
40. Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP).
Cheung CC; Barnes P; Bigras G; Boerner S; Butany J; Calabrese F; Couture C; Deschenes J; El-Zimaity H; Fischer G; Fiset PO; Garratt J; Geldenhuys L; Gilks CB; Ilie M; Ionescu D; Lim HJ; Manning L; Mansoor A; Riddell R; Ross C; Roy-Chowdhuri S; Spatz A; Swanson PE; Tron VA; Tsao MS; Wang H; Xu Z; Torlakovic EE;
Appl Immunohistochem Mol Morphol; 2019; 27(10):699-714. PubMed ID: 31584451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
